HLA-A and hepatocellular carcinoma: In this first-in-human study in HCC (NCT03132792), patients must be HLAA*02:01+ or 02:642+ and had AFP expression by immunohistochemistry (IHC) at ≥1+ in ≥20% HCC cells or serum AFP ≥ 400 ng/mL, and ≤5% IHC AFP in non-cancerous liver tissue.